A J Claxton1, Z Li, J McKendrick. 1. Eli Lilly and Company, Indianapolis, IN 46285, USA. ami.claxton@lilly.com
Abstract
BACKGROUND: Patients with depression are often not prescribed antidepressants for an adequate period of time. AIMS: The impact of antidepressant prescribing patterns on the risk of relapse or recurrence of depression is examined. METHOD: The MediPlus UK Primary Care Database was used to identify patients treated for depression with a selective serotonin reuptake inhibitor (SSRI). Records were used to construct hierarchical prescription patterns (less than 120 days, switching/augmentation, upward titration, or stable use) as indicators for the occurrence of relapse or recurrence of depression. RESULTS: Patients with stable use experienced the lowest risk of relapse or recurrence. Factors significantly associated with increased risk include prior use of anxiolytic medications, more comorbid conditions and younger age. CONCLUSIONS: The SSRI prescription pattern most consistent with recommended depression treatment guidelines was associated with the lowest risk of relapse or recurrence.
BACKGROUND:Patients with depression are often not prescribed antidepressants for an adequate period of time. AIMS: The impact of antidepressant prescribing patterns on the risk of relapse or recurrence of depression is examined. METHOD: The MediPlus UK Primary Care Database was used to identify patients treated for depression with a selective serotonin reuptake inhibitor (SSRI). Records were used to construct hierarchical prescription patterns (less than 120 days, switching/augmentation, upward titration, or stable use) as indicators for the occurrence of relapse or recurrence of depression. RESULTS:Patients with stable use experienced the lowest risk of relapse or recurrence. Factors significantly associated with increased risk include prior use of anxiolytic medications, more comorbid conditions and younger age. CONCLUSIONS: The SSRI prescription pattern most consistent with recommended depression treatment guidelines was associated with the lowest risk of relapse or recurrence.
Authors: M Brandt-Christensen; K Kvist; F M Nilsson; P K Andersen; L V Kessing Journal: J Neurol Neurosurg Psychiatry Date: 2006-06 Impact factor: 10.154
Authors: Leena K Saastamoinen; Mika Wallin; Piia Lavikainen; Marja S Airaksinen; Andre Sourander; J Simon Bell Journal: Eur J Clin Pharmacol Date: 2012-02-12 Impact factor: 2.953
Authors: R Eric Lewandowski; Mary C Acri; Kimberly E Hoagwood; Mark Olfson; Greg Clarke; William Gardner; Sarah Hudson Scholle; Sepheen Byron; Kelly Kelleher; Harold A Pincus; Samantha Frank; Sarah M Horwitz Journal: Pediatrics Date: 2013-09-16 Impact factor: 7.124
Authors: David V Sheehan; Matthew S Keene; Michael Eaddy; Stan Krulewicz; John E Kraus; David J Carpenter Journal: CNS Drugs Date: 2008 Impact factor: 5.749
Authors: Welmoed E E Meijer; E R Heerdink; Hubert G M Leufkens; Ron M C Herings; Antoine C G Egberts; Willem A Nolen Journal: Eur J Clin Pharmacol Date: 2004-02-19 Impact factor: 2.953
Authors: Rima Kaddurah-Daouk; Peixiong Yuan; Stephen H Boyle; Wayne Matson; Zhi Wang; Zhao Bang Zeng; Hongjie Zhu; George G Dougherty; Jeffrey K Yao; Guang Chen; Xavier Guitart; Paul J Carlson; Alexander Neumeister; Carlos Zarate; Ranga R Krishnan; Husseini K Manji; Wayne Drevets Journal: Sci Rep Date: 2012-09-19 Impact factor: 4.379